✦ LIBER ✦

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model for Sporadic Colorectal Cancer

✍ Scribed by Jatin Roper; Michael P. Richardson; Wei Vivian Wang; Larissa Georgeon Richard; Wei Y. Chen; Erin M. Coffee; Lydia Lee; Peng-Chieh Chen; Roderick T. Bronson; Eric S. Martin; Kenneth E. Hung

Book ID: 119432272
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 198 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(11)60425-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

808: The PI3K/mTOR inhibitor NVP-BEZ235

808: The PI3K/mTOR inhibitor NVP-BEZ235 is able to revert selumetinib resistance in colorectal cancer cellular models

✍ Martinez-Lacaci, I.; Carballo-Santana, M.; Tristante, E.; Mayor-López, L.; Grass 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB

219 POSTER NVP-BEZ235, a dual pan-PI3K/m

219 POSTER NVP-BEZ235, a dual pan-PI3K/mTOR kinase inhibitor, is effective in human lung cancer models harboring EGFR mutations

✍ C.R. Schnell; J. Vaxelaire; M. Vogelsanger; M. Hattenberger; F. Stauffer; S. Arn 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI